Gene expression profiles of the original tumors influence the generation of PDX models of lung squamous cell carcinoma.

Szczegóły
Abstrakt

Tytuł:: Gene expression profiles of the original tumors influence the generation of PDX models of lung squamous cell carcinoma.
Autorzy:: Kim Y; Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan. .
Shiba-Ishii A; Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan.
Nakagawa T; Doctoral Program in Biomedical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan.
Takeuchi T; Tsukuba Human Biobank Center, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-shi, Ibaraki, 305-8576, Japan.
Kawai H; Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan.
Matsuoka R; Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan.
Noguchi M; Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan.
Sakamoto N; Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba-shi, Ibaraki, 305-8575, Japan.; Tsukuba Human Biobank Center, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-shi, Ibaraki, 305-8576, Japan.
Źródło:: Laboratory investigation; a journal of technical methods and pathology [Lab Invest] 2021 May; Vol. 101 (5), pp. 543-553. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2023- : [New York] : Elsevier Inc.
Original Publication: Baltimore : Williams & Wilkins
MeSH Terms:: Neoplasm Transplantation*
Carcinoma, Squamous Cell/*metabolism
Lung Neoplasms/*metabolism
Animals ; Antigens, CD19/metabolism ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Gene Expression Profiling ; Lung/pathology ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Mice, SCID ; Neoplasms, Experimental ; Receptors, IgE/metabolism ; Mice
References:: Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46. (PMID: 10.1038/nrc3775)
Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol. 2019;14:377–407. (PMID: 10.1016/j.jtho.2018.12.005)
Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res. 2010;16:4864–75. (PMID: 10.1158/1078-0432.CCR-10-0199)
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25. (PMID: 10.1038/nature11404)
Gandara DR, Hammerman PS, Sos ML, Lara PN Jr., Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015;21:2236–43. (PMID: 10.1158/1078-0432.CCR-14-3039)
Day CP, Merlino G, Van, Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163:39–53. (PMID: 10.1016/j.cell.2015.08.068)
Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013. (PMID: 10.1158/2159-8290.CD-14-0001)
Jiang Y, Zhao J, Zhang Y, Li K, Li T, Chen X, et al. Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. J Transl Med. 2018;16:138. (PMID: 10.1186/s12967-018-1516-5)
Morgan KM, Riedlinger GM, Rosenfeld J, Ganesan S, Pine SR. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front Oncol. 2017;7:2. (PMID: 10.3389/fonc.2017.00002)
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48:812–30.e14. (PMID: 10.1016/j.immuni.2018.03.023)
Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12:943–53. (PMID: 10.1016/j.jtho.2017.03.010)
Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307–25. (PMID: 10.1038/s41568-019-0144-6)
Colbeck EJ, Ager A, Gallimore A, Jones GW. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front Immunol. 2017;8:1830. (PMID: 10.3389/fimmu.2017.01830)
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85. (PMID: 10.1097/JTO.0b013e318206a221)
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60. (PMID: 10.1097/JTO.0000000000000630)
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36. (PMID: 10.1186/2162-3619-1-36)
Henningsson F, Ding Z, Dahlin JS, Linkevicius M, Carlsson F, Gronvik KO, et al. IgE-mediated enhancement of CD4+ T cell responses in mice requires antigen presentation by CD11c+ cells and not by B cells. PLoS One. 2011;6:e21760. (PMID: 10.1371/journal.pone.0021760)
Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 2018;78:1308–20. (PMID: 10.1158/0008-5472.CAN-17-1987)
Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol. 2015;33:2472–80. (PMID: 10.1200/JCO.2014.60.1492)
Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14:6456–68. (PMID: 10.1158/1078-0432.CCR-08-0138)
Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13:4. (PMID: 10.1186/s13045-019-0829-z)
Kummar S, Fogarasi M, Canova A, Mota A, Ciesielski T. Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma. Br J Cancer. 2002;86:1884–7. (PMID: 10.1038/sj.bjc.6600326)
Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, et al. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clin Transl Med. 2015;4:16. (PMID: 10.1186/s40169-015-0057-2)
Wu D, Pang Y, Wilkerson MD, Wang D, Hammerman PS, Liu JS. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. Br J Cancer. 2013;109:1599–608. (PMID: 10.1038/bjc.2013.452)
Watanabe H, Ma Q, Peng S, Adelmant G, Swain D, Song W, et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014;124:1636–45. (PMID: 10.1172/JCI71545)
Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567–75. (PMID: 10.1038/ng.3967)
Moro M, Bertolini G, Caserini R, Borzi C, Boeri M, Fabbri A, et al. Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. Sci Rep. 2017;7:6689. (PMID: 10.1038/s41598-017-06912-7)
Nguyen LV, Cox CL, Eirew P, Knapp DJ, Pellacani D, Kannan N, et al. DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat Commun. 2014;5:5871. (PMID: 10.1038/ncomms6871)
Belderbos ME, Koster T, Ausema B, Jacobs S, Sowdagar S, Zwart E, et al. Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding. Blood. 2017;129:3210–20. (PMID: 10.1182/blood-2016-12-758250)
Choi H, Sheng J, Gao D, Li F, Durrans A, Ryu S, et al. Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model. Cell Rep. 2015;10:1187–201. (PMID: 10.1016/j.celrep.2015.01.040)
Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24:1277–89. (PMID: 10.1038/s41591-018-0096-5)
Hillinger S, Yang SC, Batra RK, Strieter RM, Weder W, Dubinett SM, et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br J Cancer. 2006;94:1029–34. (PMID: 10.1038/sj.bjc.6603061)
Lin Y, Sharma S, John MS. CCL21 cancer immunotherapy. Cancers. 2014;6:1098–110. (PMID: 10.3390/cancers6021098)
Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J Immunol. 2018;200:432–42. (PMID: 10.4049/jimmunol.1701269)
Fukuyama T, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, et al. Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci. 2007;98:1048–54. (PMID: 10.1111/j.1349-7006.2007.00507.x)
Substance Nomenclature:: 0 (Antigens, CD19)
0 (Receptors, IgE)
Entry Date(s):: Date Created: 20210126 Date Completed: 20210803 Latest Revision: 20240229
Update Code:: 20240229
DOI:: 10.1038/s41374-021-00529-1
PMID:: 33495573
: Czasopismo naukowe

Patient-derived xenograft (PDX) murine models are employed for preclinical research on cancers, including non-small cell lung cancers (NSCLCs). Even though lung squamous cell carcinomas (LUSCs) show the highest engraftment rate among NSCLCs, half of them nevertheless show PDX failure in immunodeficient mice. Here, using immunohistochemistry and RNA sequencing, we evaluated the distinct immunohistochemical and gene expression profiles of resected LUSCs that showed successful engraftment. Among various LUSCs, including the basal, classical, secretory, and primitive subtypes, those in the non-engrafting (NEG) group showed gene expression profiles similar to the pure secretory subtype with positivity for CK7, whereas those in the engrafting (EG) group were similar to the mixed secretory subtype with positivity for p63. Pathway analysis of 295 genes that demonstrated significant differences in expression between NEG and EG tumors revealed that the former had enriched expression of genes related to the immune system, whereas the latter had enriched expression of genes related to the cell cycle and DNA replication. Interestingly, NEG tumors showed higher infiltration of B cells (CD19 + ) and follicular dendritic cells (CD23 + ) in lymph follicles than EG tumors. Taken together, these findings suggest that the PDX cancer model of LUSC represents only a certain population of LUSCs and that CD19- and CD23-positive tumor-infiltrating immune cells in the original tumors may negatively influence PDX engraftment in immunodeficient mice.

Informacja